Letrozole versus dienogest in endometrioma recurrent after surgery: a randomized controlled trial


  • Mumtahena Amir Department of Reproductive Endocrinology and Infertility, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
  • Shakeela Ishrat Department of Reproductive Endocrinology and Infertility, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
  • Ivy Nasrin Department of Reproductive Endocrinology and Infertility, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
  • Suravi Halder Department of Reproductive Endocrinology and Infertility, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
  • Farzana Rahman Department of Reproductive Endocrinology and Infertility, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
  • M. Rifat Zia Hossain Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh




Endometrioma, Endometriosis, Letrozole, Dienogest


Background: Letrozole is a third-generation aromatase inhibitor. As there is aberrant aromatase production by endometriotic stromal cells and the growth and regression of endometriosis is estrogen-dependent, the use of letrozole to reduce the size and symptoms of endometrioma especially in recurrent cases is a promising medical intervention. Dienogest is a fourth-generation progestin which is being used for the treatment of endometriosis due to its antiproliferative and antiangiogenic properties on endometrial tissue. The present study was conducted to compare the effects of letrozole and dienogest on endometrioma recurrent after surgery.

Methods: This randomized controlled study was conducted on 38 women having recurrence of endometrioma after surgery. They were randomly assigned to receive either letrozole (2.5 mg daily) or dienogest (2 mg once daily) for 6 months. Size of the endometrioma was measured by transvaginal ultrasound and the pain (dysmenorrhoea) was measured on a visual analog scale (VAS) of 0-10, prior to treatment and after 3 and 6 months of treatment.

Results: The mean size of endometrioma was reduced from a baseline of 6.06±2.40 cm to 5.23±1.37 cm and to 4.59±1.25 cm after 3 and 6 months of treatment with letrozole. While with dienogest the reduction was from a baseline of 6.67±1.31 cm to 4.83±1.50 cm and to 3.80±1.34 cm after 3 and 6 months of treatment. The difference between the two groups was not statistically significant but dienogest yielded better result in terms of effect size. Decrease in pain (dysmenorrhoea) was highly significant with both the drugs.

Conclusions: In terms of reduction of the size of endometrioma, dienogest yields better results than letrozole. Both the drugs are highly effective in alleviating pain (dysmenorrhoea).

Author Biography

Shakeela Ishrat, Department of Reproductive Endocrinology and Infertility, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh


Department of Reproductive Endocrinology & Infertility


Park SY, Kim SH, Chae HD, Kim CH and Kang BM. Efficacy and safety of dienogest in patients with endometriosis: A single-center observational study over 12 months. Clin Exp Reprod Med. 2016;43(4):215-20.

Busacca M, Riparini J, Somigliana E, Oggioni G, Izzo S, Vignali M et al. Postsurgical ovarian failure after laparoscopic excision of bilateral endometriomas. Am J Obstet Gynecol. 2006;195(2):421-5.

Jones KD and Sutton C. Endometriosis: Emphasis on medical treatment is misleading. Bri Med J. 2002;324(7329):115.

Bazot M, Lafont C, Rouzier R, Roseau G, Thomassin-Naggara I and Daraï E. Diagnostic accuracy of physical examination, transvaginal sonography, rectal endoscopic sonography, and magnetic resonance imaging to diagnose deep infiltrating endometriosis. Fertil Steril. 2009; 92(6):1825-33.

Ferrero S, Scala C, Racca A, Calanni L, Remorgida V, Venturini PL et al. Second surgery for recurrent unilateral endometriomas and impact on ovarian reserve: a case-control study. Fertil Steril. 2015;103(5):1236-43.

Celik HG, Dogan E, Okyay E, Ulukus C, Saatli B, Uysal S et al. Effect of laparoscopic excision of endometriomas on ovarian reserve: serial changes in the serum antimüllerian hormone levels. Fertil Steril. 2012;97(6):1472-8.

Var T, Batioglu S, Tonguc E and Kahyaoglu I. The effect of laparoscopic ovarian cystectomy versus coagulation in bilateral endometrioma on ovarian reserve as determined by antral follicle count and ovarian volume: a prospective randomized study. Fertil Steril. 2011;95(7):2247-50.

Romero B, Aibar L, Navarro LM, Fontes J, Calderón MA and Mozas J. Pelvic abscess after oocyte retrieval in women with endometriosis: a case series. Iranian J Reprod Med. 2013;11(8):677.

Sitruk-Ware R. New progestogens. Drugs Aging. 2004;21(13):865-83.

Irahara M, Harada T, Momoeda M and Tamaki Y. Hormonal and histological study on irregular genital bleeding in patients with endometriosis during treatment with dienogest, a novel progestational therapeutic agent. Reprod Med Biol. 2007;6(4):223-8.

Okada H, Nakajima T, Yoshimura T, Yasuda K and Kanzaki H. The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro. Mol Hum Reprod .2001;7(4):341-7.

Angioni S, Cofelice V, Pontis A, Tinelli R, Socolov R. New trends of progestins treatment of endometriosis. Gynecol Endocrinol. 2014;30(11):769-73.

Zeitoun KM, Bulun SE. Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target. Fertil Steril. 1999;72(6):961-9.

Ferrero S, Venturini PL, Gillott DJ and Remorgida V. Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: a randomized controlled trial. Reprod Biol Endocrinol. 2011;9(1):1-7.

Delgado-Rosas F, Gomez R, Ferrero H, Gaytan F, Garcia-Velasco J et al. The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis. Reproduction. 2011;142(5):745-55.

Ansary SA, Ishrat S, Banu J, Fatima P, Nasreen F, Jahan I et al. Evaluation of the effect of aromatase inhibitor in reducing the size of endometrioma. Int J Reprod Contracept, Obstet Gynecol. 2021;10(4):1295-303.

Agarwal SK and Foster WG. Reduction in endometrioma size with three months of aromatase inhibition and progestin add-back. Bio Med Res Int. 2015;2015:878517.

Taniguchi F, Enatsu A, Ikebuchi A, Yamane E, Moriyama M, Murakami J et al. Efficacy of Norethisterone in Patients with Ovarian EndometriomaNorethisterone for treatment of endometriosis. Yonago Acta Medica. 2017;60(3):182-5.

Seal SL, Kamilya G, Mukherji J, De A, Ghosh D, Majhi AK. Aromatase inhibitors in recurrent ovarian endometriomas: report of five cases with literature review. Fertil Steril. 2011;95(1):291-e15.

Remorgida V, Abbamonte LH, Ragni N, FulcheriE and Ferrero S. Letrozole and desogestrel‐only contraceptive pill for the treatment of stage IV endometriosis. Australian and New Zealand J Obstets and Gynaecol, 2007;47(3):222-5.

Abushahin F, Goldman KN, Barbieri E, Milad M, Rademaker A, Bulun SE. Aromatase inhibition for refractory endometriosis-related chronic pelvic pain. Fertil Steril. 2011;96(4):939-42.

Ferrero S,Remorgida V, Venturini PL, and Maggiore ULR. Norethisterone acetate versus norethisterone acetate combined with letrozole for the treatment of ovarian endometriotic cysts: a patient preference study. European J Obstet Gynecol and Reprod Biol. 2014;174(2014):117-22.

Aizzi FJ. Recurrent endometrioma; outcome of medical management with dienogest. Eur Exp Biol. 2017;7(6):39.

Muzii L, Galati G, Di Tucci C, Di Feliciantonio M, Perniola G, Di Donato V et al. Medical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain. Gynecol Endocrinol. 2020;36(1):81-3.

Madny EH. Efficacy of letrozole in treatment of endometriosis-related pain. Middle East Fertil Society J. 2014;19(1):64-8.

Takayama K, Zeitoun K, Gunby RT, Sasano H, Carr BR and Bulun SE. Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil Steril. 1998;69(4):709-13.

Razzi S, Fava A, Sartini A, De Simone S, Cobellis L and Petraglia F. Treatment of severe recurrent endometriosis with an aromatase inhibitor in a young ovariectomised woman. BJOG. 2004;111(2):182-4.

Fatemi HM, Al-Turki HA, Papanikolaou EG, Kosmas L, De Sutter P, Devroey P. Successful treatment of an aggressive recurrent post-menopausal endometriosis with an aromatase inhibitor. Reprod Biomed Online. 2005;11(4):455-7.

Hefler LA, Grimm C, van Trotsenburg M, Nagele F. Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study. Fertil Steril. 2005;84(4):1033-6.

Verma A, Konje JC. Successful treatment of refractory endometriosis-related chronic pelvic pain with aromatase inhibitors in premenopausal patients. European J Obstet Gynecol Reprod Biol. 2009;143(2):112-5.

Uludag SZ, DemirtasE, Sahin Y, Aygen EM. Dienogest reduces endometrioma volume and endometriosis-related pain symptoms. J Obstet Gynaecol. 2021;41(8):1246-51.

Vignali M, Belloni GM, Pietropaolo G, Barbasetti Di Prun A, Barbera V et al. Effect of Dienogest therapy on the size of the endometrioma. Gynecol Endocrinol. 2020;36(8):723-7.

McGough JJ, Faraone SV. Estimating the size of treatment effects: moving beyond p values. Psychiatry (Edgemont). 2009; 6(10):21

Chandra A, Rho AM, Jeong K, Yu T, Jeon JH, Park SY, et al. Clinical experience of long-term use of dienogest after surgery for ovarian endometrioma. Obstet Gynecol Sci. 2018;61(1):111-7.

Badawy AM, Elnashar AM, Mosbah AA. Aromatase inhibitors or gonadotropin releasing hormone agonist for the management of uterine adenomyosis: a randomized controlled trial. Acta Obstet Gynecol Scand. 2012;91(4):489-95.






Original Research Articles